A phase I/II clinical trial on the efficacy and safety of NKT cells combined with gefitinib for advanced EGFR-mutated non-small-cell lung cancer

Table 1 Treatment schedule for the frequency of gefitinib and NKT cell in both arms of the trail

Week-4-0	Week 0–8			One cell therapy cycle
Week-4-0	Week 0–8			Week 9–12	Week 13–16	Week 17–20	Week 21–24	Week 25–28
Screening	Randomization	Experimental group (Arm A)	Donor selection, PBMCs^a acquisition and NKT cell preparation	NKT infusion	NKT infusion	NKT infusion	NKT infusion	Suspend
		Experimental group (Arm A)	Gefitinib orally once daily
		Control group (Arm B)	Gefitinib orally once daily

This schedule use one cell therapy cycle as an example, and the follow-up treatment is carried out according to the same cell therapy cycle until the trial is terminated after the disease has progressed or complete three cell therapy cycles (total 60 weeks). ^aPBMCs peripheral blood mononuclear cells

ISSN: 1471-2407